Chimeric antigen receptor (CAR) T cell therapy represents the first U.S. Food and Drug Administration approved gene therapy and these engineered cells function with unprecedented efficacy in the treatment of refractory CD19 positive hematologic malignancies. CAR translation to solid tumors is also being actively investigated; however, efficacy to date has been variable due to tumor-evolved mechanisms that inhibit local immune cell activity. To bolster the potency of CAR-T cells, modulation of the immunosuppressive tumor microenvironment with immune-checkpoint blockade is a promising strategy. The impact of this approach on hematological malignancies is in its infancy, and in this review we discuss CAR-T cells and their synergy with immune-checkpoint blockade.
Bibliographical noteFunding Information:
Acknowledgments: This work was supported in part by Asan-Minnesota Institute for Innovating Transplantation (AMIT), Global Research Development Center Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (MSIT) (NRF-2015K1A4A3046807) and the Corrigan family, and Children’s Cancer Research Fund.
© 2018 by the authors. Licensee MDPI, Basel, Switzerland.
- Adoptive T cell therapy
- Cancer immunotherapy
- Chimeric antigen receptors
- Gene editing
- Gene therapy